Indegene’s Board of Directors has approved an investment of up to Euro 8.5 million in equity shares of its wholly-owned subsidiary, Indegene Ireland Limited. The board also approved the unaudited standalone and consolidated financial results for Q2 FY26, ending September 30, 2025. Additionally, share allotments were approved under the ESOP and RSU plans, and amendments were made to the Anti-Sexual Harassment Policy.
Investment in Indegene Ireland
The Board has given the green light for an equity investment of up to Euro 8.5 million in Indegene Ireland Limited. The investment will be executed in one or more tranches. This infusion of capital aims to bolster the subsidiary’s capabilities and expand its business operations.
Q2 FY26 Financial Performance
The Board reviewed and approved the unaudited financial results for the second quarter of fiscal year 2026, ending on September 30, 2025. Both standalone and consolidated results were approved, along with the Limited Review Report from the auditors. The Financial Results are available on the company’s website and stock exchange platforms.
ESOP and RSU Plans
The board also approved the allotment of shares under the ESOP 2020 Plan and RSU 2020 Plan, incentivizing employees and aligning their interests with the company’s growth. Grants were noted under the RSU 2020 Plan, ESOP 2020 Plan and CSOP 2022 (CSOP Sub-Plan).
Policy Amendment
An amendment to the Anti-Sexual Harassment Policy was approved, reflecting the company’s commitment to maintaining a safe and respectful workplace.
Indegene Ireland Limited Details
Indegene Ireland Limited provides solutions consisting of analytics, technology and commercial, medical, regulatory and safety services to life science and healthcare organizations. The turnover for the financial year ended March 31, 2025 was €739,163.
Financial Results Overview
For the six months ending September 30, 2025, the consolidated unaudited financial results show total assets of Rs. 281 million, total revenue of Rs. 376 million, and a profit after tax of Rs. 13 million.
Source: BSE
